Avicenna.AI partners with CARPL.ai on AI to detect life-threatening conditions

Avicenna.AI’s advanced AI detection tools are now available via the CARPL platform.

Marseille, FRANCE – November 22, 2022 – Medical imaging AI specialist Avicenna.AI today
announced a distribution agreement with CARPL.ai, a technology platform that enables service provider-oriented testing, validation and deployment of AI applications to healthcare providers.

As the number of AI applications coming into the clinical realm increases, it can be challenging for healthcare providers to access, assess and then integrate these solutions into their clinical workflows. CARPL bridges this gap by acting as an intermediary platform for the development, testing, distribution and deployment of AI applications.

The CARPL platform now includes Avicenna.AI’s range of CINA solutions for neurovascular and thoraco-abdominal pathologies, which use deep learning to identify, detect and quantify life-threatening pathologies from CT medical images. The FDA-cleared and CE-Marked tools are seamlessly integrated within the clinical workflow, automatically triggering and reporting algorithm results through the systems already used by radiologists.
Using a combination of deep learning and machine learning technologies, the CINA solutions
automatically detect and prioritize cases within seconds, and assess them for severity, seamlessly alerting radiologists within their existing systems and workflow.

“CARPL.ai specializes in driving the adoption of radiology AI solutions into clinical workflows and improves patient outcomes, by enabling and empowering healthcare service providers to discover, explore, and validate cutting-edge AI and then deploy it in their environment with confidence,” said Dr. Vidur Mahajan, Chief Executive Officer of CARPL.ai. “When it comes to stroke care and other life-threatening conditions, we are delighted to now be able to offer Avicenna’s portfolio as a comprehensive solution to our customers.”

“We’re excited to partner with a leading platform like CARPL, which has a strong presence in key new markets for us, including Australia, Brazil and India,” said Cyril Di Grandi, co-founder, and CEO of Avicenna.AI. “They are also deployed in many large hospital environments, which is exactly what our solutions are designed for – delivering faster detection of critical conditions, improving radiology efficiency and supporting better patient outcomes.”

Avicenna.AI will be attending RSNA 2022, November 27 – 30. To book a meeting, email
contact@avicenna.Ai.

About Avicenna.AI 

Founded in 2018, Avicenna.AI develops medical imaging AI solutions for highly prevalent pathologies. The company uses artificial intelligence and deep learning to optimize many of a radiologist’s manual tasks. Its CINA products leverage deep learning algorithms to identify acute abnormalities and support emergency room triage. Avicenna.AI is co-founded by Cyril Di Grandi, who previously co-founded and successfully sold Olea Medical, and Dr. Peter Chang, a radiologist and internationally recognized expert in AI and deep learning. 

www.avicenna.ai

About CARPL.ai

CARPL is an end-to-end technology platform for the development, testing, distribution and
deployment of medical imaging AI applications in clinical workflows. Used by some of the world’s top AI researchers and health systems, it connects AI applications and healthcare providers helping improve access, affordability, and quality of medical care. 

www.carpl.ai

Avicenna.AI partners with deepc to revolutionize Stroke Patient Care

Logo deepc

Marseille, FRANCE – September, 27, 2022. Medical imaging specialist Avicenna.AI today announced a groundbreaking partnership with the MedTech company deepc, offering one of the leading radiology AI platforms (deepcOS), to give healthcare providers access to their stroke suite.

This move facilitates a step change in patient management for stroke, enabling rapid treatment decisions by combining a uniquely comprehensive stroke management technology with a platform that seamlessly integrates into radiologist’s clinical workflow.

Every Second Counts.

Avicenna.AI’s stroke suite gives radiologists exactly the tools they need to rapidly and automatically identify, triage, and assess patients, enabling faster decision-making and saving lives.

Avicenna.AI’s CINA stroke suite provides a full range of tools powered by deep learning to automatically identify acute abnormalities and support the emergency imaging department. It comprises two FDA-cleared, CE-marked tools for automatic triage, and one CE-marked quantification tool:

  • CINA-LVO is a triage tool that instantly flags suspected Large Vessel Occlusion (LVO) on CT angiography. Given that every minute of untreated LVO means two million neurons are lost, early diagnosis is critical.
  • Real-time trial tool CINA-ICH highlights suspected acute Intracranial Hemorrhage (ICH) on CT scans, efficiently prioritizing cases, drastically reducing the time to treatment. ICH affects over two million people worldwide with a 40-50% mortality rate within one month, so accurate early
    detection and treatment are vital.
  • CINA-ASPECTS is a quantification tool that automatically measures an ASPECT Score to assess ischemic changes in stroke. CINA-ASPECTS enables faster, more consistent, and more precise interpretations for assessing acute ischemic stroke.

To reach its potential, this technology needs to be available to those who need it. That’s where deepc comes in, by creating a cutting-edge AI ecosystem providing radiologists instant access to AI-powered technologies. The platform is changing the way AI is adopted by integrating directly into the clinical workflow. Avicenna.AI’s full stroke suite is now available through the platform, meaning more physicians and patients can benefit from its tools than ever before.

John Moulden, Chief Commercial Officer at deepc: “Our companies bring a challenger mindset to this amazing partnership, and together we offer truly revolutionary technology to healthcare providers and their radiology departments. Looking forward to working together with Avicenna.AI!“

Olivier Fuseri, Sales Manager at Avicenna.AI: “We are thrilled that our solutions for Stroke are integrated in such a groundbreaking platform as deepcOS. Together we are committed to transform the future of radiology through our combined technologies.”

Avicenna.AI signs a distribution agreement with Sectra for neurovascular AI solutions

logo-sectra

La Ciotat, France– April 27, 2022 – Medical imaging AI specialist Avicenna.AI today announced a signed distribution agreement with Sectra, an international medical imaging IT and cybersecurity company. The agreement will see Avicenna’s AI solutions for neurovascular pathologies offered through the Sectra Amplifier Marketplace, a platform for contracting, purchasing, and servicing of AI applications validated and verified for use at point of care.

Avicenna’s CINA solutions use deep learning to identify, detect and quantify life-threatening pathologies from CT medical images. The FDA-cleared and CE-Marked tools are seamlessly integrated within the clinical workflow, automatically triggering and reporting algorithm results through the systems already used by radiologists.

Stroke is a leading cause of long-term disability and the second leading cause of death, with one death every 6 seconds worldwide. There are two main types of strokes: ischemic stroke, caused by a blood clot (LVO), and hemorrhagic stroke, caused by an intracranial hemorrhage (ICH).

The AI tools to be included in Sectra’s Amplifier Marketplace include CINA-ICH, CINA-LVO, and CINA-ASPECTS.

  • CINA-ICH uses deep learning to identify suspected intracranial hemorrhage and prioritizes those cases in the worklist, dramatically reducing turnaround time for head trauma and stroke patients. (US/EU)
  • CINA-LVO is a triage tool for rapid automatic LVO detection and real-time triage and prioritization, accelerating clinical workflow and helping stroke teams in their diagnosis. (US/EU)
  • CINA-ASPECTS is an AI-based automatic quantification tool that enables faster, more consistent, and more precise interpretation for the assessment of acute ischemic stroke. (available for European Union only)

Using a combination of deep learning and machine learning technologies, the CINA solutions automatically detect and prioritize acute ICH and LVO cases within seconds, and assess them for severity, seamlessly alerting radiologists within their existing systems and workflow.

“To help healthcare providers get on the AI adoption journey, we have created the Sectra Amplifier Marketplace. We aim to facilitate easier access and usage of AI applications in medical imaging. This distribution agreement is an example of that. With Avicenna.AI tools deeply embedded in the Sectra diagnostic workspace, we provide our radiologists with enhanced diagnostic confidence for stroke cases,” says Nynke Breimer, Global Product Manager AI Radiology, Sectra.”

“We provide best-in-class AI triage tools that enable fast detection of the leading causes of stroke, leading to more efficient patient management,” said Cyril Di Grandi, co-founder, and CEO of Avicenna.AI. “We are glad to collaborate with a global partner such as Sectra. Through this agreement, we can help more clinicians to facilitate stroke decision making, ensuring a prompt therapeutic response and ultimately improving patient outcomes.”

About Avicenna.AI
Founded in 2018, Avicenna.AI develops medical imaging AI solutions for highly prevalent pathologies. The company uses artificial intelligence and deep learning to optimize many of a radiologist’s manual tasks. Its CINA products leverage deep learning algorithms to identify acute abnormalities and support emergency room triage. Avicenna.AI is co-founded by Cyril Di Grandi, who previously co-founded and successfully sold Olea Medical, and Dr. Peter Chang, a radiologist and internationally recognized expert in AI and deep learning.

About Sectra
With 30 years of innovation and more than 2,000 installations around the globe, Sectra is a leading imaging IT provider for health systems worldwide. Sectra offers a complete enterprise solution comprised of imaging modules (radiology, cardiology, pathology, orthopedics, and ophthalmology), and a robust VNA. Over the last nine consecutive years, Sectra has been awarded Best in KLAS for the highest customer satisfaction. For more information, visit Sectra website.

Avicenna.AI Partners With UpCare To Deliver Innovative Value Based Solution to Canadian Health Providers

Logo Upcare

Toronto & Marseille – July 27th , 2021 –Medical imaging AI specialist Avicenna.AI today announced a partnership with UpCare Partners & Associates to distribute, deliver and implement a fully integrated stroke detection AI solution for any PACS Platform in Canada.

With this partnership, Avicenna provides UpCare with its FDA-approved CINA Head triage AI solution for neurovascular emergencies, which detects two of the leading causes of stroke – intracranial hemorrhage (ICH) and large vessel occlusion (LVO) – from CT-scan imaging.

Using a combination of deep learning and machine learning technologies, CINA Head automatically detects and prioritizes acute ICH and LVO cases within 20 seconds, seamlessly alerting the radiologist within their existing systems and workflow.

CINA’s ICH detection capability was validated using data from 814 cases conducted at more than 250 imaging centers across the United States, with 96% accuracy, 91.4% sensitivity and 97.5% specificity. The product’s LVO detection capability was validated based on 476 cases, with 97.7% accuracy 97.9% sensitivity and 97.6% specificity.

“Canada is a Leading Country in the world of Neuroscience, the partnership will enrich physicians’ resources for accessing and qualifying Stroke events and ICH seamlessly in a record time; we are always looking to provide our customers with enhanced and expanded imaging capabilities” said Benoit Sai, Co-Founder & CCO, UpCare Partners & Associates. “By adding Avicenna’ proven and validated solutions to our Neuroscience ecosystem, Canadian healthcare providers have access to innovative automated advanced brain imaging technology, allowing them to deliver better patient care.”

Cyril Di Grandi, co-founder and CEO, Avicenna.AI, said, “Our partnership with a Canadian distributor focussing on ecosystems approach toward the continuum of care in the field of neurosciences combined with expertise in medical imaging, medical devices and ai like UpCare Inc is a testament to the excellent accuracy, sensitivity and specificity data that has been gathered during our validation phase. We look forward to working with our new partner to bring the benefits of our AI-powered stroke triage solution to the emergency room and beyond in Canada.”

About UpCare Partners & Associates
Founded in 2019, UpCare Partners & Associates, a Canadian MedTech Company, is the gateway to the Canadian market for start-ups and international OEM. The company provides the best expertise in each field by committing special attention and a focussed approach to your product on a Pan Canada basis. In this challenging time for Healthcare Institutions UpCare Partners & Associates works with its partners on Value Based Solutions for the best Patient Outcome and Continuum of Care. www.upcarepartners.com

Viz.ai and Avicenna.AI Partner to Launch World-class AI-Driven Intelligent Care Coordination for Pulmonary Embolism and Aortic Disease

Logo Viz

SAN FRANCISCO and PARIS – July 15, 2021Viz.ai, the world leader in AI-driven intelligent care coordination has partnered with Avicenna.AI, a global leader in artificial intelligence solutions, to enable intelligent care coordination and improve patient triage of patients suffering from pulmonary embolism (PE) and aortic disease (AD). The collaboration will pave the way for faster clinical decision making and care for patients suffering from these two life threatening conditions.

Diagnosis and care coordination of patients suffering from PE and aortic disease can be challenging. Avicenna.AI’s FDA-approved algorithms for PE and Type A and Type B aortic dissection (AD), leveraged on the Viz intelligent care coordination platform, will empower multidisciplinary care teams to easily coordinate patient care by sending notifications paired with dynamic imaging and detailed patient information to each provider’s desktop or mobile device as soon as a PE or an aortic dissection is detected. As part of Viz.ai’s commercial aortic module offering, access to imaging and workflows supporting the coordination of care for patients with abdominal aortic aneurysm (AAA), thoracic aortic aneurysm (TAA), rupture, stenosis and transection will be available in addition to the AD algorithm. Similarly, the PE algorithm will be available on Viz.ai’s commercial PE module.

“The addition of AI powered workflows should decrease the time from diagnosis to treatment and help to coordinate care for patients suffering from life-threatening PE and aortic disease, as it has in the treatment of ischemic stroke. It will help to facilitate faster and easier treatment decisions across health systems, and this should improve outcomes for patients,” said Dr. Richard Saxon, interventional radiologist Tri-City Medical Center.

The Viz Platform is clinically proven and validated by Medicare, which reimburses hospitals directly via a New Technology Add-On Payment for Viz LVO, the time-saving ischemic stroke product. Pairing team alerts enhanced by AI with high-fidelity mobile image viewing, patient information and full-stack secure communication enables multidisciplinary teams to make faster treatment decisions for patients. The result increases access to care and improves outcomes for patients.

“We are proud to become a trusted partner of Viz.ai, who is committed to giving access to high-standard healthcare systems worldwide. Thanks to our AI-based solutions, we hope to facilitate an optimal medical response within a short time frame and improve patient care. We look forward to bringing the benefits of our pulmonary embolism and aortic dissection triage tools to the emergency room and beyond,” said Cyril Di Grandi, chief executive officer of Avicenna.AI.

PE is a potentially deadly form of venous thromboembolic disease, a common cause of cardiovascular death, and is associated with multiple inherited and acquired risk factors affecting hundreds of thousands of people every year globally. PE occurs when a blood clot gets lodged in an artery in the lung, blocking blood flow to part of the lung. Similar to PE, aortic disease is potentially deadly and can require urgent surgical intervention to prevent death.

“We’re delighted to partner with Avicenna to bring intelligent care coordination to the peripheral vascular and vascular fields. This will form part of a broader Viz.AI platform, where any patient with life threatening diseases can benefit from AI powered triage, fast mobile communication and synchronized care coordination,” said Dr. Chris Mansi, Viz.ai CEO and co-founder. “This partnership will bring the advantages of artificial intelligence to more patients and help hospitals achieve better clinical outcomes.”

About Viz.ai, Inc.
Viz.ai is the leader in AI-driven intelligent care coordination. Viz.ai’s mission is to fundamentally improve how healthcare is delivered in the world, through intelligent software that promises to reduce time to treatment, improve access to care, and increase the speed of diffusion of medical innovation. Viz.ai’s clinically validated platform leverages advanced deep learning to communicate time-sensitive information to specialists who can more quickly and easily make treatment decisions for the patient. In February 2018, the U.S. Food and Drug Administration (FDA) granted a De Novo clearance for Viz LVO, the first-ever computer-aided triage and notification software. Viz.ai announced its second FDA clearance for Viz CTP through the 510(k) pathway, offering healthcare providers an important tool for automated cerebral perfusion image analysis. A third FDA clearance was granted in 2020 for Viz ICH, which uses AI to automatically detect suspected intracranial hemorrhage on CT imaging. In 2020, CMS granted Viz.ai the first New Technology Add-on Payment (NTAP) for artificial intelligence software for Viz LVO.

Viz.ai is located in San Francisco and Tel Aviv and backed by leading Silicon Valley investors, including Kleiner Perkins, Google Ventures, Greenoaks, CRV, Threshold Ventures, Innovation Endeavors, Susa Ventures, Scale Venture Partners and Insight Partners.

Click here and find out more about Viz.ai.

Avicenna.AI Joins Nuance AI Marketplace for Diagnostic Imaging

Logo Nuance

Marseille, France – 29th June, 2021Avicenna.AI today announced that their FDA-cleared applications for neurovascular emergencies, CINA-ICH & CINALVO, are available on the Nuance® AI Marketplace, the first and largest portal with one-stop access to a wide range of AI diagnostic models from within the industry’s most widely used radiology reporting platform.

CINA offers radiologists an unparalleled solution for triaging patients with positive impact on high occurrence life-threatening pathologies. CINA-ICH and CINA-LVO automatically detect and prioritize acute intracranial hemorrhage and large vessel occlusion cases within 20 seconds, seamlessly alerting the radiologist within their existing systems and workflow.

The Nuance AI Marketplace functions like an app store dedicated to radiology. It gives algorithm developers consolidated, at-scale access to users of Nuance PowerScribe™, the radiology reporting system trusted by approximately 80 percent of U.S. radiologists across more than 9,000 connected healthcare facilities. Radiologists can discover, test, and use AI models from within their familiar Nuance PowerScribe reporting and workflow orchestration solutions to increase reporting efficiency and quality, and to help care teams improve patient outcomes and healthcare costs. A built-in feedback channel lets users share real-world results with developers for model refinement and post-market surveillance. Hospital systems benefit with simplified purchasing and metrics showing AI usage, costs, and performance.

“We are glad to partner with a global partner such as Nuance who shares our same values to put patient care at the core of their business. Together we are committed to transforming medical imaging by empowering radiologists in their daily tasks. Thanks to this partnership and our combined solutions, we aim to advance the future of healthcare,said Cyril Di Grandi, Chief Executive Officer and co-founder of Avicenna.AI.

Arterys & Avicenna.AI Join Forces on AI Stroke Detection

Logo Arterys

San Francisco, CA & Paris, FRANCE – December 1, 2020 – Medical imaging AI specialist Avicenna.AI today announced that its FDA-cleared CINA Head triage AI solution will be offered by cloud-based imaging platform Arterys. Supporting the treatment of stroke and neurovascular emergencies, CINA Head detects intracranial hemorrhages (ICHs) and large vessel occlusions (LVOs) from CT-scan imaging.

Arterys has fully integrated the CINA Head AI algorithms and will make them available via its FDA-cleared MICA platform to its installed base in the coming weeks. The platform’s cloud SaaS model enables CINA Head’s workflow-enhancing algorithms to be delivered instantly to any of Arterys’ existing customers.

“Given CMS’s recent NTAP reimbursement decision regarding AI-powered LVO detection, we believe that AI is finally ready to transform clinical practice, and we’re excited to make Avicenna’s AI innovations available to doctors around the world,” said John Axerio-Cilies, Arterys co-founder and CEO. “We’ve tuned the experience for seamless workflow integration—towards the ends of efficient and effective analysis of non-contrast head CTs and CTAs and accurate detection of intracranial hemorrhages and LVO strokes.”

Using a combination of deep learning and machine learning technologies, CINA Head automatically detects and prioritizes acute ICH and LVO cases within 20 seconds, seamlessly alerting the radiologist within their existing systems and workflow.

“Arterys’s platform is the most agile in this new internet-based era of medical AI,” said Cyril Di Grandi, co-founder and CEO of Avicenna.AI. “They help companies like us go from code-to-clinic in weeks not years, giving radiologists the ability to instantly enhance their workflows with our AI – whenever they want to.”

About Arterys

Arterys is the market leader and the world’s first internet platform for medical imaging. Its objective is to transform healthcare by transforming radiology. The Arterys platform is 100% web-based, AI-powered, and FDA-cleared, unlocking simple clinical solutions. For more information on Arterys, please Arterys website.

Avicenna.AI Partners With Canon Medical on AI Stroke Detection

Logo Canon

Paris, FRANCE – November 10, 2020 – Medical imaging AI specialist Avicenna.AI today announced a partnership with Canon Medical Systems Corporation to deliver a fully integrated stroke detection AI solution for Canon’s Automation Platform.

With this partnership, Avicenna provides Canon with its FDA-approved CINA Head triage AI solution for neurovascular emergencies, which detects two of the leading causes of stroke – intracranial hemorrhage (ICH) and large vessel occlusion (LVO) – from CT-scan imaging.

Using a combination of deep learning and machine learning technologies, CINA Head automatically detects and prioritizes acute ICH and LVO cases within 20 seconds, seamlessly alerting the radiologist within their existing systems and workflow.

CINA’s ICH detection capability was validated using data from 814 cases conducted at more than 250 imaging centers across the United States, with 96% accuracy, 91.4% sensitivity and 97.5% specificity. The product’s LVO detection capability was validated based on 476 cases, with 97.7% accuracy 97.9% sensitivity and 97.6% specificity.

Toshiki Kato, General Manager of Healthcare IT, Canon Medical Systems, said, “Our partnership with Avicenna demonstrates our commitment to providing our customers with AI solutions that help them to improve the quality of care. With its proven ability to help radiologists to identify pathologies quickly, but also to highlight those that require the most urgent care, CINA Head is exactly the kind of innovative solution that we want to offer clinicians.”

Cyril Di Grandi, co-founder and CEO, Avicenna.AI, said, “Our partnership with a medical imaging modality leader like Canon Medical Systems is a testament to the excellent accuracy, sensitivity and specificity data that has been gathered during our validation phase. We look forward to working with our new partner to bring the benefits of our AI-powered stroke triage solution to the emergency room and beyond.”

About Canon Medical Systems Corporation
Canon Medical offers a full range of diagnostic medical imaging solutions including CT, X-Ray, Ultrasound, Vascular and MR, as well as a full suite of Healthcare IT solutions, across the globe. In line with our continued Made for Life philosophy, patients are at the heart of everything we do. Our mission is to provide medical professionals with solutions that support their efforts in contributing to the health and wellbeing of patients worldwide. Our goal is to deliver optimum health opportunities for patients through uncompromised performance, comfort and safety features.

At Canon Medical, we work hand in hand with our partners – our medical, academic and research community. We build relationships based on transparency, trust and respect. Together as one, we strive to create industry-leading solutions that deliver an enriched quality of life. For more information, visit the Canon Medical website: https://global.medical.canon.